logo

Deposit $200 to get a $100 trading bonus.

Use the promo code AMANAWEB.

Sign up now.*T&Cs Apply.

Terms & Conditions

  1. Offer valid for new users signing up on amana.
  2. How to Qualify for $100 Trading Bonus:
    • Sign up via the website.
    • Complete onboarding by providing the required details.
    • Enter promo code AMANAWEB at the final step.
    • Deposit $100 or more before your first trade.
    • Make your first trade.
  3. Once all steps are completed, you’ll receive a $100 non-withdrawable trading bonus.
  4. Bonuses are credited during the first week of every month.
  5. The bonus can only be used for trading and cannot be withdrawn.
  6. The campaign is exclusive to selected amana customers.
  7. amana reserves the right to cancel bonuses in cases of suspected fraud.
KYMR icon

KYMR

Lightning icon

111.23 USD

-0.78%

Today

-0.01%

1D

Market is open

Sun

Closed

Mon

3:00 AM ~ 12:00 PM

Tue

12:00 AM ~ 12:00 PM

Wed

12:00 AM ~ 12:00 PM

Thu

12:00 AM ~ 12:00 PM

Fri

12:00 AM ~ 12:00 PM

Sat

Closed

Loading chart...
1D
5D
1M
3M
1Y
MAX

Information

Name

Kymera Therapeutics Leveraged

Currency

USD

Standard Leverage

1X

Lightning Icon

Enhanced Leverage

3X

Lightning Icon

Overnight Fees Buy

-0.0183%

Overnight Fees Sell

0.0016%

Market Cap

8.94B

Avg Daily Volume

799.17K

52 Week High

130.05 USD

52 Week Low

36.65 USD

Trading Hours

See hours

Overnight Fees Calculator

ExposureUnits
USD
Daily Overnight Fee %Daily Overnight Fee $
BUYS-0.01830%$(0.183)
SELLS0.00160%$0.016

*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.

Business Summary

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Top News

Kymera

-0.01%

Weekly Recap: Q2 2026 revenue surge and KT-621 Phase 2b enrollment

tradingview.com

2d ago

No Image

Kymera

-0.01%

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

tradingview.com

5d ago

No Image

Kymera

-0.01%

Key facts: Kymera (KYMR) Q2 $65M; $1.5B cash; KT-621 data end-2026

tradingview.com

6d ago

No Image

Show more

Frequently Asked Questions

What are healthcare stocks and why are they important to investors?

Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.

Are healthcare stocks less volatile?

Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.

What drives growth in healthcare investments?

Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.

What are the risks of investing in healthcare?

Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.